Prognostic significance of mean corpuscular volume in patients with pancreatic ductal adenocarcinoma and multimodal treatment

Aim of the study. - Mean corpuscular volume (MCV) has shown mounting evidence as a prognostic indicator in a number of malignancies. The aim of this study was to examine the prognostic potential of pretherapeutic MCV among patients with pancreatic ductal adenocarcinoma (PDAC) who underwent upfront resection or resection after neoadjuvant treatment (NT). Patients and methods. - Consecutive patients with PDAC who underwent pancreatic resection between 1997 and 2019 were included in this study. Neoadjuvantly treated patients' serum MCV was measured before NT and before surgery. In patients undergoing upfront resection serum MCV was measured before surgery. Median MCV values were used as cut-off to distinguish high from low MCV values. Results. - Five hundred and forty-nine (438 upfront resected and 111 neoadjuvantly treated) patients were included in this study. Multivariate analysis revealed, that high MCV before and after NT, were independent negative prognostic factors for overall survival (P < 0.01, respectively). Furthermore, the median MCV value from before to after NT increased significantly (P < 0.001, Wilcoxon signed-rank test) and was (P = 0.03, Wilcoxon rank sum test) associated with tumor response to NT. Conclusion. - High MCV is an independent adverse prognostic factor in patients with resectable neoadjuvantly treated PDAC and may qualify as useful indicator to help physicians to provide personalized prognostication. (c) 2023 Les Auteurs. Publi<acute accent>e par Elsevier Masson SAS. Cet article est publi<acute accent>e en Open Access sous licence CC BY (http://creativecommons.org/licenses/by/4.0/).